Your browser doesn't support javascript.
loading
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Agarwal, Neeraj; McGregor, Bradley; Maughan, Benjamin L; Dorff, Tanya B; Kelly, William; Fang, Bruno; McKay, Rana R; Singh, Parminder; Pagliaro, Lance; Dreicer, Robert; Srinivas, Sandy; Loriot, Yohann; Vaishampayan, Ulka; Goel, Sanjay; Curran, Dominic; Panneerselvam, Ashok; Schwickart, Martin; Choueiri, Toni K; Pal, Sumanta.
Afiliación
  • Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: neeraj.agarwal@hci.utah.edu.
  • McGregor B; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Maughan BL; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Dorff TB; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Kelly W; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
  • Fang B; Astera Cancer Care, East Brunswick, NJ, USA.
  • McKay RR; University of California San Diego, San Diego, CA, USA.
  • Singh P; Department of Oncology, Mayo Clinic, Scottsdale, AZ, USA.
  • Pagliaro L; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Dreicer R; University of Virginia Cancer Center, Charlottesville, VA, USA.
  • Srinivas S; Division of Medical Oncology, Stanford University Medical Center, Stanford, CA, USA.
  • Loriot Y; Department of Cancer Medicine, Gustave Roussy Institute, INSERM 981, University Paris-Saclay, Villejuif, France.
  • Vaishampayan U; Karmanos Cancer Center, Wayne State University, Detroit, MI, USA; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
  • Goel S; Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Curran D; Exelixis, Alameda, CA, USA.
  • Panneerselvam A; Exelixis, Alameda, CA, USA.
  • Schwickart M; Exelixis, Alameda, CA, USA.
  • Choueiri TK; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Pal S; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Lancet Oncol ; 23(7): 899-909, 2022 07.
Article en En | MEDLINE | ID: mdl-35690072
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido